Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nalmefene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 known ✓ | P41143 | 12/20 | 1.00 |
| ▸ | OPRM1 known ✓ | P35372 | 10/20 | 1.00 |
| ▸ | OPRK1 known ✓ | P41145 | 9/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.80 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.80 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.80 |
| ▸ | PKM | P14618 | 1/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.78 |
| ▸ | LMNA | P02545 | 1/20 | 0.77 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.77 |
| ▸ | MAPT | P10636 | 2/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.70 |
| ▸ | USP2 | O75604 | 1/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.70 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.70 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nalmefene SCHEMBL18457569 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1NR1I2KCNH2 | |
| Nalmefene SCHEMBL12646154 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1NR1I2KCNH2 | |
| Nalmefene SCHEMBL18827079 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1NR1I2KCNH2 | |
| Nalmefene SCHEMBL14124638 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1NR1I2KCNH2 | |
| Nalmefene SCHEMBL12233286 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1NR1I2KCNH2 | |
| Nalmefene SCHEMBL629213 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1NR1I2KCNH2 | |
| Nalmefene SCHEMBL3114702 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1NR1I2KCNH2 | |
| Nalmefene SCHEMBL18104559 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1NR1I2KCNH2 | |
| Nalmefene SCHEMBL19500879 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1NR1I2KCNH2 | |
| Nalmefene SCHEMBL35230 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1NR1I2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020223894-A1 | OPIOID RECEPTOR ANTAGONIST PRODRUGS | NIRSUM LABORATORIES, INC. (US) | 2020-11-12 | — | — | WO | disclosed |
| EP-1758452-B1 | METABOLICALLY STABLE ANALGESICS AND PAIN MEDICATIONS | HUMAN BIOMOLECULAR RES INST (US) | 2017-01-25 | — | — | EP | disclosed |
| US-8481501-B2 | Synthesis of metabolically stable analgesics, pain medications and other agents | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2013-07-09 | — | — | US | disclosed |
| US-20100190728-A1 | Synthesis Of Metabolically Stable Analgesics, Pain Medications And Other Agents | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2010-07-29 | — | — | US | disclosed |
| US-7671204-B2 | N-demethylation of N-methyl morphinans | MALLINCKRODT INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-7671204-B2 | N-demethylation of N-methyl morphinans | MALLINCKRODT INC. (US) | 2010-03-02 | — | — | US | disclosed |
| WO-2009078990-A1 | N-DEMETHYLATION OF N-METHYL MORPHINANS | MALLINCKRODT INC. (US) | 2009-06-25 | — | — | WO | disclosed |
| US-20090156815-A1 | N-demethylation of N-methyl morphinans | SpecGx LLC | 2009-06-18 | — | — | US | disclosed |
| US-20090156815-A1 | N-demethylation of N-methyl morphinans | SpecGx LLC | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156815-A1 | N-demethylation of N-methyl morphinans | OPRM1, PNMT, OPRD1 | OPRD1 3/4885OPRM1 1/4885OPRK1 6/4885 |
| US-20100190728-A1 | Synthesis Of Metabolically Stable Analgesics, Pain Medications And Other Agents | OPRK1, OPRL1, OPRM1 | OPRD1 4/4885OPRM1 3/4885OPRK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.